Lantheus Holdings, Inc. (LNTH)
About Lantheus Holdings, Inc.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.5B
- Net income
- $233.6M
- Total assets
- $2.2B
- Market cap
- $6.6B
- Gross margin
- 61.1%
- Operating margin
- 20.2%
- Net margin
- 15.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.5B
- Cost of revenue
- $599.7M
- Gross profit
- $942.0M
- Operating expenses
- $631.1M
- Operating income
- $310.8M
- Income tax
- $80.2M
- Net income
- $233.6M
- EPS (basic)
- $3.46
- EPS (diluted)
- $3.41
Balance sheet
- Total assets
- $2.2B
- Current assets
- $900.0M
- Total liabilities
- $1.1B
- Current liabilities
- $333.4M
- Shareholders’ equity
- $1.1B
Cash flow
- Operating cash flow
- $390.1M
- Investing cash flow
- -$627.2M
- Financing cash flow
- -$316.6M
- Net cash flow
- -$553.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.6B
- P/E ratio
- 30.7
- EPS (diluted)
- $3.41
- Shares outstanding
- 62.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 25, 2015
Lantheus Holdings, Inc. (LNTH) Stock Price
- Profitable — net income of $233.6M in FY2025.
- Revenue grew 263% from FY2021 to FY2025.
- Gross margin of 61.1%, net margin 15.2%.
- Trading 6% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 30.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lantheus Holdings, Inc..
Write a review
News about Lantheus Holdings, Inc.
News & sentiment via Polygon.io
Lantheus Holdings, Inc.: frequently asked questions
Is Lantheus Holdings, Inc. an American company?
Lantheus Holdings, Inc. is a US-based company headquartered in North Billerica, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Lantheus Holdings, Inc. headquartered?
Lantheus Holdings, Inc. is headquartered in North Billerica, Massachusetts, United States.
Is Lantheus Holdings, Inc. publicly traded?
Yes — Lantheus Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol LNTH on the NASDAQ.
What does Lantheus Holdings, Inc. do?
Lantheus Holdings, Inc. is an American Medical Devices company in the Health & Beauty sector.
